Pharmaceuticals - Oncology Products & Hyaluronate Injection | Reliance Life Sciences - LifeSciences
- AzatiRel® (Azacitidine)
- BortiRel® (Bortezomib)
- ErlotiRel® (Erlotinib)
- ImatiRel® (Imatinib)
- Isabis® (Sodium hyaluronate)
- LeuproRel® (Leuprolide)
- ReliCitabine® (Capecitabine)
- ReliDomide® (Lenalidomide)
- ReliTrexed® (Pemetrexed)
- SynoLife™ / SynoLife One™ (Hyaluronate Injection)
- TemoRel® (Temozolomide)
- TerliRel® (Terlipressin)
- SorafiRel™ (Sorafenib)
The Pharmaceuticals initiative of Reliance Life Sciences is focused on developing Active Pharmaceutical Ingredients (API) and Finished Dosage Forms (FDFs) for domestic and global markets in the categories of:
- Oncology products
- Hyaluronate Injection
Reliance Life Sciences markets Oncology APIs and formulated products.
The pharmaceutical products are manufactured in cGMP facilities:
Plant 3 - Kilo scale facility for Pharmaceutical APIs with containment facilities for oncology products.
Plant 5 - A manufacturing facility for hyaluronic acid formulations.
Plant 6 - A manufacturing facility for oncology formulations (oral solid dosages and injectibles).